凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
广誉远(600771)公告正文

广誉远:2018年第一季度报告

公告日期 2018-04-24
股票简称:广誉远 股票代码:600771
公司代码:600771                               公司简称:广誉远




             广誉远中药股份有限公司
                   2018 年第一季度报告




                      二○一八年四月二十四日
                                                                   广誉远中药股份有限公司 2018 年第一季度报告




                                                        目         录


一、重要提示 ...............................................................................................................2

二、公司基本情况 ........................................................................................................2

三、重要事项 ...............................................................................................................5

四、附录 ......................................................................................................................8




                                                               1
                                                  广誉远中药股份有限公司 2018 年第一季度报告




一、重要提示

1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、
     完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。


1.2 公司全体董事出席董事会审议季度报告。


1.3 公司负责人张斌、主管会计工作负责人傅淑红及会计机构负责人(会计主管人员)
     侯宽余保证季度报告中财务报表的真实、准确、完整。


1.4 本公司第一季度报告未经审计。



二、公司基本情况

2.1 主要财务数据
                                                                            单位:元   币种:人民币

                                                                                   本报告期末比
                                  本报告期末                  上年度末
                                                                                 上年度末增减(%)

总资产                            2,529,210,504.37           2,517,620,674.29                  0.46

归属于上市公司股东的净资产         1,965,468,313.13          1,913,826,432.98                  2.70

                                 年初至报告期末         上年初至上年报告期末    比上年同期增减(%)

经营活动产生的现金流量净额           -85,678,012.92           -156,470,625.96                不适用

                                 年初至报告期末         上年初至上年报告期末    比上年同期增减(%)

营业收入                            293,501,724.02            201,579,716.81                  45.60

归属于上市公司股东的净利润           51,641,880.15             24,250,041.19                 112.96

归属于上市公司股东的扣除非经常
                                     51,044,808.39             23,457,560.59                 117.60
性损益的净利润

加权平均净资产收益率(%)                        2.66                    1.41     增加 1.25 个百分点

基本每股收益(元/股)                            0.15                    0.07                114.29

稀释每股收益(元/股)                            0.15                    0.07                114.29




                                             2
                                                                     广誉远中药股份有限公司 2018 年第一季度报告



 非经常性损益项目和金额
 √适用 □不适用
                                                                                                 单位:元     币种:人民币
                                             项目                                                         本期金额

 非流动资产处置损益                                                                                              -38,487.90

 越权审批,或无正式批准文件,或偶发性的税收返还、减免

 计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家政策规定、
                                                                                                               1,087,308.90
 按照一定标准定额或定量持续享受的政府补助除外

 计入当期损益的对非金融企业收取的资金占用费

 委托他人投资或管理资产的损益

 债务重组损益

 除上述各项之外的其他营业外收入和支出                                                                                -8,126.22

 少数股东权益影响额(税后)                                                                                     -321,530.58

 所得税影响额                                                                                                   -122,092.44

                                             合计                                                               597,071.76



 2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持
       股情况表
                                                                                                                     单位:股

                          股东总数(户)                                                         12,548

                                                      前十名股东持股情况

                                                                                持有       质押或冻结情况
                                                    期末持股         比例
           股东名称(全称)                                                  有限售条件   股份                       股东性质
                                                      数量           (%)                             数量
                                                                              股份数量    状态

                                                                                                                 境内非国有
西安东盛集团有限公司                                81,991,639       23.22   27,943,374   质押    53,560,000
                                                                                                                       法人

财富证券-浦发银行-财富证券-广誉远安
                                                    16,000,000        4.53   16,000,000   无                           其他
宫清心集合资产管理计划

宁波鼎盛金禾股权投资合伙企业(有限合伙)            12,701,533        3.60   12,701,533   无                           其他

华能贵诚信托有限公司-华能信托悦晟 3
                                                    11,197,067        3.17                无                           其他
号单一资金信托

国寿安保基金-建设银行-人寿保险-中国人寿
                                                    10,599,521        3.00                无                           其他
保险(集团)公司委托国寿安保基金混合型组合

樟树市磐鑫投资管理中心(有限合伙)                  10,161,227        2.88   10,161,227   无                           其他




                                                                 3
                                                           广誉远中药股份有限公司 2018 年第一季度报告



全国社保基金一零四组合                   10,099,998        2.86                 无                      其他

北京东富新投投资管理中心(有限合伙)      8,134,129        2.30                 无                      其他

郑文平                                    7,250,103        2.05                 无                 境内自然人

长安基金-广发银行-华鑫信托-鑫康
                                          7,000,000        1.98    7,000,000    无                      其他
财富 6 号单一资金信托

                                       前十名无限售条件股东持股情况

                                                          持有无限售条件流             股份种类及数量
                        股东名称
                                                              通股的数量             种类               数量

西安东盛集团有限公司                                              54,048,265     人民币普通股      54,048,265

华能贵诚信托有限公司-华能信托悦晟 3 号单一资金信托                11,197,067     人民币普通股      11,197,067

国寿安保基金-建设银行-人寿保险-中国人寿保险(集团)
                                                                  10,599,521     人民币普通股      10,599,521
公司委托国寿安保基金混合型组合

全国社保基金一零四组合                                            10,099,998     人民币普通股      10,099,998

北京东富新投投资管理中心(有限合伙)                               8,134,129     人民币普通股       8,134,129

郑文平                                                             7,250,103     人民币普通股       7,250,103

长安国际信托股份有限公司-长安信托-广誉远第二期员工
                                                                   6,205,619     人民币普通股       6,205,619
持股集合资金信托计划

陕西省国际信托股份有限公司-陕国投祥瑞 5 号结构化
                                                                   5,577,564     人民币普通股       5,577,564
证券投资集合资金信托计划

陕西省国际信托股份有限公司-陕国投祥瑞 6 号结构化证
                                                                   3,664,919     人民币普通股       3,664,919
券投资集合资金信托计划

蒋仕波                                                             3,210,000     人民币普通股       3,210,000

                                                          华能贵诚信托有限公司-华能信托悦晟 3 号单一资金信托所

                                                          持股份系公司控股股东西安东盛集团有限公司间接增持股

                                                          份,长安国际信托股份有限公司-长安信托-广誉远第二期

                                                          员工持股集合资金信托计划所持股份为公司员工持股计划
上述股东关联关系或一致行动的说明
                                                          所购买股票,除此之外东盛集团与其他股东之间无关联关

                                                          系;鼎盛金禾与磐鑫投资之间有关联关系,其他股东之间

                                                          公司未知是否存在关联关系,也未知是否属于《上市公司

                                                          收购管理办法》中规定的一致行动人。



 2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股
     东持股情况表
 □适用 √不适用




                                                      4
                                            广誉远中药股份有限公司 2018 年第一季度报告



三、重要事项
3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
√适用 □不适用
                                                                                 单位:元

               科目            本期数                 上年同期数         变动比例(%)

货币资金                       455,054,098.29           280,946,210.16            61.97

应收票据                       146,975,522.93           242,798,351.87           -39.47

预付款项                        44,373,115.20            12,936,480.96           243.01

其他流动资产                     6,543,450.36           307,601,990.42           -97.87

开发支出                           999,206.36             4,567,571.86           -78.12

预收款项                         9,525,000.06            23,002,143.13           -58.59

应付职工薪酬                     8,989,036.59            14,388,536.36           -37.53

营业收入                       293,501,724.02           201,579,716.81            45.60

销售费用                       135,205,950.70            92,487,248.49            46.19

管理费用                        32,653,257.71            24,136,749.12            35.28

财务费用                         3,129,549.54               217,311.44          1340.12

投资收益                         2,130,356.05              -786,919.35           不适用

利润总额                        69,181,273.00            36,320,880.93            90.47

归属于母公司股东的净利润        51,641,880.15            24,250,041.19           112.96

经营活动产生的现金流量净额      -85,678,012.92         -156,470,625.96           不适用

投资活动产生的现金流量净额     251,594,505.21          -395,746,305.53           不适用

筹资活动产生的现金流量净额       8,191,395.84           -39,859,383.32           不适用


    (1)货币资金比期初增加17,410.79万元,增幅61.97%,主要是因为报告期内山
西广誉远国药有限公司(以下简称“山西广誉远”)购买的结构性存款产品到期收回;
    (2)应收票据比期初减少9,582.28万元,减幅39.47%,主要是因为报告期内背书
转让和贴现的年初持有的银行承兑汇票。
    (3)预付款项比期初增加3,143.66万元,增幅243.01%,主要是因为山西广誉远
预付广告费及采购款增加。
    (4)其他流动资产比期初减少30,105.85万元,减幅97.87%,主要是因为山西广
誉远收回到期的结构性存款产品30,000万元。




                                        5
                                         广誉远中药股份有限公司 2018 年第一季度报告



    (5)开发支出比期初减少356.84万元,减幅78.12%,主要是因为北京杏林誉苑结
转杏林壹号APP的延伸开发计入无形资产。
    (6)预收款项比期初减少1,347.71万元,减幅58.59%,主要是因为前期预收款项
发货确认收入。
    (7)应付职工薪酬比期初减少539.95万元,减幅37.53%,主要因为支付上期预提
工资。
    (8)营业收入比上年同期增加9,192.20万元,增幅45.60%,主要因为本报告期公
司各项市场活动的开展及广告投放的影响,继续带动公司传统中药业务板块持续增长,
达47.2%。
    (9)销售费用比上年同期增加4,271.87万元,增幅46.19%,主要因为报告期公司
收入增长,市场投入的费用随之增加。
    (10)管理费用比上年同期增加851.65万元,增幅35.28%,主要是人员较上年同
期增加使工资类费用增加546.8万元以及报告期山西广誉远研究开发费用投入增加
387.50万元。
    (11)财务费用比上年同期增加291.22万元,增幅1,340.12%,主要因为报告期山
西广誉远银行借款利息增加95.6万元及银行承兑汇票贴现息增加138.26万元。
    (12)投资收益比上年同期增加291.72万元,主要因为报告期内公司购买的结构性
存款产品到期获得收益262.50万元。
    (13 )利润总额、 归属于母公司净利润分别 比上年同期增加3,286.04万元和
2,739.18 万元,增幅分别为 90.47%和112.96% ,主要因为①报告期营业收入增加
9,192.20万元;②报告期购买的结构性存款产品到期获得收益262.50万元;
    (14) 经营活动产生的现金流量净额比上年同期增加7,079.26万元,主要因为报
告期公司营业收入增加9,192.20万元,同时公司加大了应收账款催收力度,使得当期销
售回款收到的现金增加6,945.76万元。
    (15)投资活动产生的现金流量净额比上年同期增加6.4亿元,主要因为报告期公
司购买的结构性存款产品到期收回。
    (16)筹资活动产生的现金流量净额比上年同期增加4,805.08万元,主要因为上年
同期山西广誉远归还到期银行借款4,000万元。




                                     6
                                            广誉远中药股份有限公司 2018 年第一季度报告



3.2 重要事项进展情况及其影响和解决方案的分析说明
□适用 √不适用


3.3 报告期内超期未履行完毕的承诺事项
□适用 √不适用


3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重
    大变动的警示及原因说明
√适用 □不适用
    公司通过全面展开“好孕中国”、 “秋收行动”等各种市场活动,继续完善、深
化销售渠道,公司品牌效应日益凸显,市场知名度不断提升。同时,公司不断加强预算
管理、强化成本控制,使得盈利能力进一步提高,故预计年初至下一报告期期末的累计
净利润与上年同期相比增长 90%以上。




                                     公司名称           广誉远中药股份有限公司
                                     法定代表人         张斌
                                     日期               2018 年 4 月 22 日




                                       7
                                                      广誉远中药股份有限公司 2018 年第一季度报告



四、附录

4.1 财务报表

                                       合并资产负债表
                                         2018 年 3 月 31 日

编制单位:广誉远中药股份有限公司
                                                              单位:元   币种:人民币   审计类型:未经审计

                      项目                                    期末余额                    年初余额

流动资产:

   货币资金                                                     455,054,098.29             280,946,210.16

   以公允价值计量且其变动计入当期损益的金融资产

   衍生金融资产

   应收票据                                                     146,975,522.93             242,798,351.87

   应收账款                                                     874,363,136.57             735,363,341.23

   预付款项                                                      44,373,115.20              12,936,480.96

   应收利息                                                                                  2,929,166.67

   应收股利

   其他应收款                                                    92,478,736.62              84,121,399.92

   买入返售金融资产

   存货                                                         214,974,559.54             182,357,154.76

   持有待售资产

   一年内到期的非流动资产

   其他流动资产                                                    6,543,450.36            307,601,990.42

     流动资产合计                                              1,834,762,619.51          1,849,054,095.99

非流动资产:

   发放贷款和垫款

   可供出售金融资产                                              18,300,000.00              18,300,000.00

   持有至到期投资

   长期应收款

   长期股权投资                                                    7,035,983.39              7,530,627.34

   投资性房地产

   固定资产                                                      53,644,961.50              54,612,552.13

   在建工程                                                     489,197,153.41             456,875,509.98




                                                  8
                                   广誉远中药股份有限公司 2018 年第一季度报告



                        项目             期末余额              年初余额

   工程物资

   固定资产清理

   生产性生物资产

   油气资产

   无形资产                                 97,502,148.70        93,646,874.29

   开发支出                                    999,206.36          4,567,571.86

   商誉

   长期待摊费用                             10,061,128.57        11,059,175.77

   递延所得税资产                            2,776,300.78          2,776,300.78

   其他非流动资产                           14,931,002.15        19,197,966.15

     非流动资产合计                        694,447,884.86       668,566,578.30

       资产总计                          2,529,210,504.37      2,517,620,674.29

流动负债:

   短期借款                                119,721,750.00       110,000,000.00

   衍生金融负债

   应付票据                                  3,290,158.49          4,637,065.45

   应付账款                                150,978,129.58       166,463,548.20

   预收款项                                  9,525,000.06        23,002,143.13

   卖出回购金融资产款

   应付手续费及佣金

   应付职工薪酬                              8,989,036.59        14,388,536.36

   应交税费                                 82,280,700.07        93,923,861.32

   应付利息                                                         164,937.50

   应付股利

   其他应付款                               85,923,143.55        91,767,340.53

   应付分保账款

   持有待售负债

   一年内到期的非流动负债

   其他流动负债

     流动负债合计                          460,707,918.34       504,347,432.49

非流动负债:

   长期借款



                               9
                                                   广誉远中药股份有限公司 2018 年第一季度报告



                       项目                              期末余额                    年初余额

    应付债券

    其中:优先股

           永续债

    长期应付款

    长期应付职工薪酬

    专项应付款                                                  8,820,000.00             8,820,000.00

    预计负债

    递延收益                                                   14,136,133.33           14,323,633.33

    递延所得税负债

    其他非流动负债                                             10,000,000.00           10,000,000.00

      非流动负债合计                                           32,956,133.33           33,143,633.33

       负债合计                                               493,664,051.67          537,491,065.82

所有者权益

    股本                                                      353,111,304.00          353,111,304.00

    其他权益工具

    其中:优先股

           永续债

    资本公积                                             1,753,790,314.96            1,753,790,314.96

    减:库存股

    其他综合收益

    专项储备

    盈余公积                                                   29,615,319.69           29,615,319.69

    一般风险准备

    未分配利润                                            -171,048,625.52             -222,690,505.67

    归属于母公司所有者权益合计                           1,965,468,313.13            1,913,826,432.98

    少数股东权益                                               70,078,139.57           66,303,175.49

      所有者权益合计                                     2,035,546,452.70            1,980,129,608.47

       负债和所有者权益总计                              2,529,210,504.37            2,517,620,674.29




法定代表人:张斌                 主管会计工作负责人:傅淑红                    会计机构负责人:侯宽余




                                              10
                                                      广誉远中药股份有限公司 2018 年第一季度报告



                                       母公司资产负债表
                                        2018 年 3 月 31 日
编制单位:广誉远中药股份有限公司
                                                             单位:元   币种:人民币   审计类型:未经审计

                     项目                                 期末余额                     年初余额

流动资产:

  货币资金                                                     3,971,683.10               17,318,905.84

  以公允价值计量且其变动计入当期损益的金融资产

  衍生金融资产

  应收票据

  应收账款

  预付款项

  应收利息

  应收股利

  其他应收款                                                 740,488,440.33              675,561,687.10

  存货

  持有待售资产

  一年内到期的非流动资产

  其他流动资产

    流动资产合计                                             744,460,123.43              692,880,592.94

非流动资产:

  可供出售金融资产                                            10,000,000.00               10,000,000.00

  持有至到期投资

  长期应收款

  长期股权投资                                             2,200,912,637.83            2,200,912,637.83

  投资性房地产

  固定资产                                                     2,025,163.40                2,045,231.51

  在建工程

  工程物资

  固定资产清理

  生产性生物资产

  油气资产

  无形资产




                                                 11
                                                     广誉远中药股份有限公司 2018 年第一季度报告



                    项目                                 期末余额                年初余额

 开发支出

 商誉

 长期待摊费用

 递延所得税资产

 其他非流动资产

   非流动资产合计                                         2,212,937,801.23       2,212,957,869.34

     资产总计                                             2,957,397,924.66       2,905,838,462.28

流动负债:

 短期借款

 以公允价值计量且其变动计入当期损益的金融负债

 衍生金融负债

 应付票据

 应付账款                                                     2,142,289.77           2,142,289.77

 预收款项                                                   115,622,492.98         115,836,622.85

 应付职工薪酬                                                  687,625.07              744,249.36

 应交税费                                                      792,324.16              502,740.22

 应付利息

 应付股利

 其他应付款                                                  61,359,108.88           6,835,547.45

 持有待售负债

 一年内到期的非流动负债

 其他流动负债

   流动负债合计                                             180,603,840.86         126,061,449.65

非流动负债:

 长期借款

 应付债券

 其中:优先股

        永续债

 长期应付款

 长期应付职工薪酬

 专项应付款

 预计负债



                                                12
                                               广誉远中药股份有限公司 2018 年第一季度报告



                     项目                          期末余额                 年初余额

  递延收益

  递延所得税负债

  其他非流动负债                                       10,000,000.00           10,000,000.00

    非流动负债合计                                     10,000,000.00           10,000,000.00

      负债合计                                        190,603,840.86          136,061,449.65

所有者权益:

  股本                                                353,111,304.00          353,111,304.00

  其他权益工具

  其中:优先股

         永续债

  资本公积                                          3,037,005,722.26         3,037,005,722.26

  减:库存股

  其他综合收益

  专项储备

  盈余公积

  未分配利润                                         -623,322,942.46          -620,340,013.63

    所有者权益合计                                  2,766,794,083.80         2,769,777,012.63

      负债和所有者权益总计                          2,957,397,924.66         2,905,838,462.28




法定代表人:张斌             主管会计工作负责人:傅淑红                会计机构负责人:侯宽余




                                          13
                                                          广誉远中药股份有限公司 2018 年第一季度报告



                                                合并利润表
                                               2018 年 1—3 月
编制单位:广誉远中药股份有限公司
                                                                 单位:元    币种:人民币   审计类型:未经审计

                         项目                                    本期金额                     上期金额

一、营业总收入                                                     293,501,724.02              201,579,716.81

其中:营业收入                                                     293,501,724.02              201,579,716.81

      利息收入

      已赚保费

      手续费及佣金收入

二、营业总成本                                                     227,491,342.05              165,306,200.38

其中:营业成本                                                      51,187,546.29               42,464,903.10

      利息支出

      手续费及佣金支出

      退保金

      赔付支出净额

      提取保险合同准备金净额

      保单红利支出

      分保费用

      税金及附加                                                     5,315,037.81                5,999,988.23

      销售费用                                                     135,205,950.70               92,487,248.49

      管理费用                                                      32,653,257.71               24,136,749.12

      财务费用                                                       3,129,549.54                  217,311.44

      资产减值损失

  加:公允价值变动收益(损失以“-”号填列)

      投资收益(损失以“-”号填列)                                 2,130,356.05                 -786,919.35

      其中:对联营企业和合营企业的投资收益

      资产处置收益(损失以“-”号填列)                              -38,487.90                  615,336.48

      汇兑收益(损失以“-”号填列)

      其他收益                                                         136,000.00                  150,000.00

三、营业利润(亏损以“-”号填列)                                 68,238,250.12               36,251,933.56

  加:营业外收入                                                       951,308.90                   78,947.37

  减:营业外支出                                                            8,286.02                10,000.00



                                                     14
                                                         广誉远中药股份有限公司 2018 年第一季度报告



四、利润总额(亏损总额以“-”号填列)                            69,181,273.00             36,320,880.93

  减:所得税费用                                                  13,764,428.77               9,310,121.47

五、净利润(净亏损以“-”号填列)                                55,416,844.23             27,010,759.46

  (一)按经营持续性分类

    1.持续经营净利润(净亏损以“-”号填列)                      55,416,844.23             27,010,759.46

    2.终止经营净利润(净亏损以“-”号填列)

  (二)按所有权归属分类

    1.少数股东损益                                                 3,774,964.08               2,760,718.27

    2.归属于母公司股东的净利润                                    51,641,880.15             24,250,041.19

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益的税后净额

    (一)以后不能重分类进损益的其他综合收益

      1.重新计量设定受益计划净负债或净资产的变动

      2.权益法下在被投资单位不能重分类进损益的其他
综合收益中享有的份额

    (二)以后将重分类进损益的其他综合收益

      1.权益法下在被投资单位以后将重分类进损益的其
他综合收益中享有的份额
      2.可供出售金融资产公允价值变动损益

      3.持有至到期投资重分类为可供出售金融资产损益

      4.现金流量套期损益的有效部分

      5.外币财务报表折算差额

      6.其他

  归属于少数股东的其他综合收益的税后净额

七、综合收益总额                                                  55,416,844.23             27,010,759.46

  归属于母公司所有者的综合收益总额                                51,641,880.15             24,250,041.19

  归属于少数股东的综合收益总额                                     3,774,964.08               2,760,718.27

八、每股收益:

  (一)基本每股收益(元/股)                                                0.15                      0.07

  (二)稀释每股收益(元/股)                                                0.15                      0.07




法定代表人:张斌                     主管会计工作负责人:傅淑红                   会计机构负责人:侯宽余




                                                    15
                                                          广誉远中药股份有限公司 2018 年第一季度报告



                                               母公司利润表
                                               2018 年 1—3 月
编制单位:广誉远中药股份有限公司
                                                              单位:元      币种:人民币   审计类型:未经审计
                        项目                                     本期金额                    上期金额

一、营业收入                                                         6,313,189.37                6,862,267.38

  减:营业成本

      税金及附加                                                       16,283.80                 1,130,042.80

      销售费用

      管理费用                                                       9,280,296.15               10,045,377.24

      财务费用                                                              -461.75               -118,623.53

      资产减值损失

  加:公允价值变动收益(损失以“-”号填列)

      投资收益(损失以“-”号填列)

      其中:对联营企业和合营企业的投资收益

      资产处置收益(损失以“-”号填列)                                                           615,336.48

      其他收益

二、营业利润(亏损以“-”号填列)                                 -2,982,928.83               -3,579,192.65

  加:营业外收入

  减:营业外支出

三、利润总额(亏损总额以“-”号填列)                              -2,982,928.83                -3,579,192.65

    减:所得税费用

四、净利润(净亏损以“-”号填列)                                  -2,982,928.83                -3,579,192.65

  (一)持续经营净利润(净亏损以“-”号填列)                      -2,982,928.83                -3,579,192.65

  (二)终止经营净利润(净亏损以“-”号填列)

五、其他综合收益的税后净额

  (一)以后不能重分类进损益的其他综合收益

   1.重新计量设定受益计划净负债或净资产的变动

   2.权益法下在被投资单位不能重分类进损益的其他
综合收益中享有的份额
  (二)以后将重分类进损益的其他综合收益

    1.权益法下在被投资单位以后将重分类进损益的其
他综合收益中享有的份额

    2.可供出售金融资产公允价值变动损益




                                                     16
                                                        广誉远中药股份有限公司 2018 年第一季度报告



    3.持有至到期投资重分类为可供出售金融资产损益

    4.现金流量套期损益的有效部分

    5.外币财务报表折算差额

    6.其他

六、综合收益总额                                                 -2,982,928.83            -3,579,192.65

七、每股收益:

    (一)基本每股收益(元/股)

    (二)稀释每股收益(元/股)




法定代表人:张斌                    主管会计工作负责人:傅淑红                   会计机构负责人:侯宽余




                                                   17
                                                      广誉远中药股份有限公司 2018 年第一季度报告



                                        合并现金流量表
                                         2018 年 1—3 月
编制单位:广誉远中药股份有限公司
                                                             单位:元    币种:人民币    审计类型:未经审计

                             项目                                       本期金额              上期金额

一、经营活动产生的现金流量:

  销售商品、提供劳务收到的现金                                          171,005,094.83       101,547,487.72

  客户存款和同业存放款项净增加额

  向中央银行借款净增加额

  向其他金融机构拆入资金净增加额

  收到原保险合同保费取得的现金

  收到再保险业务现金净额

  保户储金及投资款净增加额

  处置以公允价值计量且其变动计入当期损益的金融资产净增加额

  收取利息、手续费及佣金的现金

  拆入资金净增加额

  回购业务资金净增加额

  收到的税费返还                                                           280,100.00

  收到其他与经营活动有关的现金                                            7,870,135.27           228,947.37

    经营活动现金流入小计                                                179,155,330.10       101,776,435.09

  购买商品、接受劳务支付的现金                                           53,769,896.52        49,218,771.19

  客户贷款及垫款净增加额

  存放中央银行和同业款项净增加额

  支付原保险合同赔付款项的现金

  支付利息、手续费及佣金的现金

  支付保单红利的现金

  支付给职工以及为职工支付的现金                                         42,933,289.74        27,126,853.08

  支付的各项税费                                                         67,162,581.94        74,583,078.33

  支付其他与经营活动有关的现金                                          100,967,574.82       107,318,358.45

    经营活动现金流出小计                                                264,833,343.02       258,247,061.05

      经营活动产生的现金流量净额                                        -85,678,012.92      -156,470,625.96

二、投资活动产生的现金流量:

  收回投资收到的现金                                                    600,000,000.00




                                                 18
                                                        广誉远中药股份有限公司 2018 年第一季度报告



                           项目                                     本期金额            上期金额

  取得投资收益收到的现金                                              5,554,166.67

  处置固定资产、无形资产和其他长期资产收回的现金净额                                      1,550,329.04

  处置子公司及其他营业单位收到的现金净额

  收到其他与投资活动有关的现金

    投资活动现金流入小计                                            605,554,166.67        1,550,329.04

  购建固定资产、无形资产和其他长期资产支付的现金                     53,959,661.46      97,296,634.57

  投资支付的现金                                                    300,000,000.00     300,000,000.00

  质押贷款净增加额

  取得子公司及其他营业单位支付的现金净额

  支付其他与投资活动有关的现金

    投资活动现金流出小计                                            353,959,661.46     397,296,634.57

      投资活动产生的现金流量净额                                    251,594,505.21     -395,746,305.53

三、筹资活动产生的现金流量:

  吸收投资收到的现金                                                                       550,000.00

  其中:子公司吸收少数股东投资收到的现金

  取得借款收到的现金                                                159,721,750.00

  发行债券收到的现金

  收到其他与筹资活动有关的现金

    筹资活动现金流入小计                                            159,721,750.00         550,000.00

  偿还债务支付的现金                                                150,000,000.00      40,000,000.00

  分配股利、利润或偿付利息支付的现金                                  1,530,354.16         409,383.32

  其中:子公司支付给少数股东的股利、利润

  支付其他与筹资活动有关的现金

    筹资活动现金流出小计                                            151,530,354.16      40,409,383.32

      筹资活动产生的现金流量净额                                      8,191,395.84      -39,859,383.32

四、汇率变动对现金及现金等价物的影响

五、现金及现金等价物净增加额                                        174,107,888.13     -592,076,314.81

  加:期初现金及现金等价物余额                                      280,946,210.16     968,463,899.81

六、期末现金及现金等价物余额                                        455,054,098.29     376,387,585.00




法定代表人:张斌                       主管会计工作负责人:傅淑红              会计机构负责人:侯宽余




                                                   19
                                                        广誉远中药股份有限公司 2018 年第一季度报告



                                       母公司现金流量表
                                           2018 年 1—3 月
编制单位:广誉远中药股份有限公司
                                                            单位:元   币种:人民币   审计类型:未经审计

                           项目                                 本期金额                  上期金额

一、经营活动产生的现金流量:

  销售商品、提供劳务收到的现金

  收到的税费返还

  收到其他与经营活动有关的现金                                    75,500,200.71           119,107,681.90

    经营活动现金流入小计                                          75,500,200.71           119,107,681.90

  购买商品、接受劳务支付的现金

  支付给职工以及为职工支付的现金                                   3,209,796.00             2,732,000.01

  支付的各项税费                                                       16,283.80            1,251,835.53

  支付其他与经营活动有关的现金                                    85,601,473.65           107,265,203.02

    经营活动现金流出小计                                          88,827,553.45           111,249,038.56

      经营活动产生的现金流量净额                                 -13,327,352.74             7,858,643.34

二、投资活动产生的现金流量:

  收回投资收到的现金

  取得投资收益收到的现金

  处置固定资产、无形资产和其他长期资产收回的现金净额                                        1,550,000.00

  处置子公司及其他营业单位收到的现金净额

  收到其他与投资活动有关的现金

    投资活动现金流入小计                                                                    1,550,000.00

  购建固定资产、无形资产和其他长期资产支付的现金                       19,870.00                1,579.00

  投资支付的现金                                                                          836,211,112.00

  取得子公司及其他营业单位支付的现金净额

  支付其他与投资活动有关的现金

    投资活动现金流出小计                                               19,870.00          836,212,691.00

      投资活动产生的现金流量净额                                       -19,870.00        -834,662,691.00

三、筹资活动产生的现金流量:

  吸收投资收到的现金

  取得借款收到的现金

  收到其他与筹资活动有关的现金




                                                   20
                                                        广誉远中药股份有限公司 2018 年第一季度报告



                           项目                                 本期金额                   上期金额

    筹资活动现金流入小计

  偿还债务支付的现金

  分配股利、利润或偿付利息支付的现金

  支付其他与筹资活动有关的现金

    筹资活动现金流出小计

      筹资活动产生的现金流量净额

四、汇率变动对现金及现金等价物的影响

五、现金及现金等价物净增加额                                        -13,347,222.74         -826,804,047.66

  加:期初现金及现金等价物余额                                      17,318,905.84          853,759,712.10

六、期末现金及现金等价物余额                                         3,971,683.10           26,955,664.44




法定代表人:张斌                       主管会计工作负责人:傅淑红                    会计机构负责人:侯宽余




4.2 审计报告
□适用 √不适用




                                                   21
数据加载中...
prevnext
手机查看股票